Alzamend Neuro, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
02262M506
SEDOL
N/A
CIK
0001677077
www.alzamend.com
LEI:
©
FIGI: BBG00ZMXG7M8
ALZN
Alzamend Neuro, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Alzamend Neuro, Inc.
ISIN
US02262M5067
TICKER
ALZN
MIC
XNAS
REUTERS
ALZN.OQ
BLOOMBERG
ALZN US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mi., 18.12.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced it will have a poster presentation at th...
weiterlesen
Alzamend Neuro
Research & Analysen Termsheet Terminal
Permalink
Do., 12.12.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), reported its financial results for the second quarter en...
weiterlesen
Alzamend Neuro
Research & Analysen Termsheet Terminal
Permalink
Di., 19.11.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has finished analyzing the final ...
weiterlesen
Alzamend Neuro
Research & Analysen Termsheet Terminal
Permalink
Mi., 16.10.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received the final full data ...
weiterlesen
Alzamend Neuro
Research & Analysen Termsheet Terminal
Permalink
Di., 15.10.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received formal written notic...
weiterlesen
Alzamend Neuro
Research & Analysen Termsheet Terminal
Permalink
Do., 10.10.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that CEO Stephan Jackman will participate...
weiterlesen
Alzamend Neuro
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S